

Q1 2024 Earnings Presentation
May 2024

Forward-Looking and Non-GAAP Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are information of a non-historical nature and are subject to risks and uncertainties that are beyond JBT's ability to control. These forward-looking statements include, among others, statements relating to our business and our results of operations, a potential transaction with Marel hf. ("Marel"), our strategic plans, our restructuring plans and expected cost savings from those plans, and our liquidity. The factors that could cause our actual results to differ materially from expectations include, but are not limited to, the following factors: the occurrence of any event, change or other circumstances that could give rise to the termination or abandonment of the offer; the expected timing and likelihood of completion of the proposed transaction with Marel, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the offer that could reduce anticipated benefits or cause the parties to abandon the transaction; the possibility that our stockholders may not approve the issuance of new shares of common stock in the offer; the risk that Marel and/or JBT may not be able to satisfy the conditions to the proposed offer in a timely manner or at all; the risk that the proposed offer and its announcement could have an adverse effect on the ability of JBT and Marel to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; the risk that problems may arise in successfully integrating the businesses of Marel and JBT, which may result in the combined company not operating as effectively and efficiently as expected; the risk that the combined company may be unable to achieve cost-cutting synergies or that it may take longer than expected to achieve those synergies; fluctuations in our financial results; unanticipated delays or acceleration in our sales cycles; deterioration of economic conditions; including impacts from supply chain delays and reduced material or component availability; inflationary pressures, including increases in energy, raw material, freight, and labor costs; disruptions in the political, regulatory, economic and social conditions of the countries in which we conduct business; changes to trade regulation, quotas, duties or tariffs; fluctuations in currency exchange rates; changes in food consumption patterns; impacts of pandemic illnesses, food borne illnesses and diseases to various agricultural products; weather conditions and natural disasters; the impact of climate change and environmental protection initiatives; acts of terrorism or war, including the ongoing conflicts in Ukraine and the Middle East; termination or loss of major customer contracts and risks associated with fixed-price contracts, particularly during periods of high inflation; customer sourcing initiatives; competition and innovation in our industries; difficulty in implementing our pure play food and beverage strategy, including our ability to execute on strategic investments, merger or acquisition opportunities; our ability to develop and introduce new or enhanced products and services and keep pace with technological developments; difficulty in developing, preserving and protecting our intellectual property or defending claims of infringement; catastrophic loss at any of our facilities and business continuity of our information systems; cyber-security risks such as network intrusion or ransomware schemes; loss of key management and other personnel; potential liability arising out of the installation or use of our systems; our ability to comply with U.S. and international laws governing our operations and industries; increases in tax liabilities; work stoppages; fluctuations in interest rates and returns on pension assets; a systemic failure of the banking system in the United States or globally impacting our customers' financial condition and their demand for our goods and services; availability of and access to financial and other resources; and other factors described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in JBT's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission and in any subsequently filed Quarterly Reports on Form 10-Q. JBT cautions shareholders and prospective investors that actual results may differ materially from those indicated by the forward-looking statements. JBT undertakes no obligation to publicly update or revise any forwardlooking statements whether as a result of new information, future developments, subsequent events or changes in circumstances or otherwise.

JBT provides non-GAAP financial measures in order to increase transparency in our operating results and trends. These non-GAAP measures eliminate certain costs or benefits from, or change the calculation of, a measure as calculated under U.S. GAAP. By eliminating these items, JBT provides a more meaningful comparison of our ongoing operating results, consistent with how management evaluates performance. Management uses these non-GAAP measures in financial and operational evaluation, planning and forecasting.

These calculations may differ from similarly-titled measures used by other companies. The non-GAAP financial measures disclosed are not intended to be used as a substitute for, nor should they be considered in isolation of, financial measures prepared in accordance with U.S. GAAP.



Important Additional Information

Important Notices

This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In particular, this presentation is not an offer of securities for sale in the United States, Iceland, the Netherlands, or Denmark.

Note to U.S. Shareholders

It is important that U.S. shareholders understand that the offer and any related offer documents are subject to disclosure and takeover laws and regulations in Iceland and other European jurisdictions, which may be different from those of the United States. The offer will be made in compliance with the U.S. tender offer rules, including Regulation 14E under the Exchange Act and any exemption available to JBT in respect of securities of foreign private issuers provided by Rule 14d-1(d) under the Exchange Act.

Important Additional Information

No offer of JBT securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption from registration, and applicable European regulations, including the Icelandic Prospectus Act no. 14/2020 and the Icelandic Takeover Act no. 108/2007 on takeovers. In connection with the proposed offer, JBT is expected to file with the SEC a Registration Statement on Form S-4, which will contain a proxy statement/prospectus in connection with the proposed offer. Additionally, JBT has filed with the Financial Supervisory Authority of the Central Bank of Iceland (the "FSA)" for approval a draft prospectus in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 for the shares to be issued in connection with the proposed offer and for the listing and admission to trading on Nasdaq Iceland of JBT securities (the "prospectus"). JBT has also filed a draft offer document with the FSA. SHAREHOLDERS OF JBT AND MAREL ARE URGED TO READ THE FORM S-4, INCLUDING THE PROXY STATEMENT/ PROSPECTUS CONTAINED THEREIN, THE PROSPECTUS, AND THE OFFER DOCUMENT, AS APPLICABLE, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED WITH THE SEC OR THE FSA CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. JBT and Marel shareholders will be able to obtain a free copy of the proxy statement/prospectus (when available), as well as other filings containing information about JBT, without charge, at the SEC's website at www.sec.gov, and on JBT's website at https://ir.jbtc.com/overview/default.aspx. Following approval by the FSA, you may obtain a free copy of the prospectus on the FSA's website at www.jbtc.com/overview/default.aspx. Following approv

Participants in the Solicitation

JBT and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of JBT's common stock in respect of the offer to Marel shareholders. Information about the directors and executive officers of JBT is set forth in the proxy statement for JBT's 2024 Annual Meeting of Stockholders, which was filed with the SEC on March 28, 2024, and in the other documents filed after the date thereof by JBT with the SEC. Investors may obtain additional information regarding the interests of such participants by reading the proxy statement/prospectus regarding the proposed offer when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.



First Quarter 2024 Results


Key Takeaways

- Achieved sixth consecutive quarter of year-over-year (YoY) improvement in adjusted EBITDA margin
- The first quarter, which is typically the seasonally slowest quarter, delivered results that were in line with JBT's expectations
- Adjusted EBITDA margin increased 60 basis points versus prior year primarily driven by cost savings from JBT's supply chain initiatives and restructuring program; this was partially offset by higher incentive compensation and labor inflation
- Beyond the operational improvements, YoY EPS was positively impacted by ~\$9M, or ~\$0.22 per share (after tax), of net interest expense improvement

Q1 2024	YoY	vs. Q4 2023
tions		
\$389	(4%)	(7%)
\$664	(2%)	(2%)
\$392	1%	(12%)
\$23	33%	(57%)
\$57	6%	(29%)
14.6%	60 bps	(360 bps)
\$0.71	34%	(57%)
\$0.85	39%	(39%)
	\$389 \$664 \$392 \$23 \$57 14.6% \$0.71	\$389 (4%) \$664 (2%) \$392 1% \$23 33% \$57 6% \$14.6% 60 bps \$0.71 34%



Demonstrating Resiliency with Orders Across Diverse End Markets and a High Level of Recurring Revenue




Key Takeaways

- In Q1 2024, experienced healthy demand in ready meals, convenience foods, and fruit / juice processing; good demand in the Middle East / Europe
- Q1 2024 orders declined versus prior year given select market softness in North America, including continuation of the slower investment profile in the
 poultry market; there was also an orders timing issue in warehouse automation (pipeline remains robust)
- North American poultry market fundamentals have continued to improve, leading to better cash flow and profitability as well as a more positive sentiment for investment among JBT customers; JBT's pipeline activity is improving, which is expected to translate to increased orders during Q2 2024
- Q1 2024 recurring revenue was 52% versus 56% in the prior year



Note: Figures may have immaterial differences due to rounding.

Strong Balance Sheet to Support JBT Initiatives





Key Takeaways

- Outstanding total debt of ~\$650M (as of March 31, 2024) is at low-cost, fixed rates
- The first quarter is generally the seasonally lowest free cash flow quarter and reflects preparation for expected revenue growth throughout the remainder of 2024; that said, there are opportunities to continue to improve working capital management
- Continuing to expect a free cash flow conversion rate of greater than 100% for the full year 2024



Reiterating 2024 Outlook for Adj. EBITDA and Adj. EPS

\$ millions except EPS	FY 2024 Guidance
Revenue	\$1,735 – \$1,765
Income from Continuing Operations	\$142 – \$154
Adjusted EBITDA (1)	\$295 – \$310
Adjusted EBITDA Margin	17.0 – 17.5%
GAAP EPS	\$4.40 - \$4.80
Adjusted EPS (1)	\$5.05 – \$5.45
Free Cash Flow Conversion	>100%

Additional Full Year 2024 Guidance Details

- Continue to forecast YoY organic revenue growth of 4 6%; no longer expecting ~1% benefit from foreign exchange translation
- Updated full year GAAP guidance to reflect the following items, which do not impact adjusted EBITDA or adjusted EPS
 - Anticipate full year M&A related costs of \$30 \$35M
 - Estimate ~\$4M net interest expense impact from bridge financing costs, which relate to the bridge facility secured in anticipation of the Marel transaction
 - Expect a discrete tax benefit of \$8 \$9M in Q2 2024 from tax planning actions
- Expect net interest income of ~\$2M, which includes the estimated bridge financing costs
- Full year tax rate is forecast to be 22 23 percent, which is prior to discrete items

2024 Quarterly Guidance Color

- Continue to forecast a revenue split of ~47% in first half of 2024 and ~53% in the second half of 2024
- Adjusted EBITDA margin expected to improve during each sequential quarter in 2024 as market conditions are expected to improve and strategic sourcing actions flow through to the results
- For Q2 2024 and each subsequent quarter of 2024, expect yearover-year adjusted EBITDA margin improvement



Target Timeline for Marel Transaction Next Steps


May	June	July	August	September	October	November	December -	Q1 2025
2024								2025
S-4								•
May Target prelimir S-4 filing	nary	<u>Late-J</u> Target approv	SEC					
			JBT	Stockholder Vote				
Vol	untary Takeove	r Offer	Targ	e-August: let JBT special stockholder ting / stockholder vote				
Ta	nd of May: arget offer launch, pe proval of offer docul			Acceptance per	riod		Year-end 2024: Target offer closing	
	Naso	laq Listing						
	Targ	-June: get commencemen al application	t of	Review	of Nasdaq Iceland applic	eation	Year-end 2024: Target secondary listing approval	
Regulatory								
Ongoing: Preparation a required filing	nd submission of s			Regulatory revie	ew		Year-end 2024: Target regulatory approval	>

Targeting to close transaction by year-end 2024, subject to approval by JBT stockholders, regulatory clearances, acceptance of the tender offer by at least 90% of Marel shareholders, and satisfaction or waiver of other closing conditions



Expect to Deliver Compelling Synergies for Combination with Marel

Identified & Expected Annual Run-Rate Cost Synergies



OPEX

- Scale combined company's R&D and selling efforts across larger organization
- Address overlap, including IT systems, public company costs, third party contracts, and certain back-office resources

COGS

- Consolidate and optimize purchasing, standardize components through value add/value engineering processes, and expand exposure to best cost country sourcing
- Leverage manufacturing capacity across broader footprint



Additional Potential Revenue Synergies



Cross-selling capabilities through diversified and scaled product offering



Go-to market effectiveness



Enhanced customer service



Leveraging combined R&D for innovation



Enhanced digital offering, automation capabilities, and sustainable products



Appendix Non-GAAP Reconciliations

Non-GAAP Financial Measures

The non-GAAP financial measures presented in this report may differ from similarly-titled measures used by other companies. The non-GAAP financial measures are not intended to be used as a substitute for, nor should they be considered in isolation of, financial measures prepared in accordance with U.S. GAAP.

- EBITDA and Adjusted EBITDA: We define EBITDA as earnings before income taxes, interest expense and depreciation and amortization. We
 define Adjusted EBITDA as EBITDA before restructuring, pension expense other than service cost, and M&A related costs.
- Adjusted income from continuing operations and Adjusted diluted earnings per share from continuing operations: We adjust earnings for
 restructuring expense, M&A related costs, which include integration costs and the amortization of inventory step-up from business combinations,
 advisory and transaction costs for both potential and completed M&A transactions and strategy ("M&A related costs"), and impact on tax
 provision from remeasurement of deferred taxes for material tax rate changes.
- Free cash flow: We define free cash flow as cash provided by continuing operating activities, less capital expenditures, plus proceeds from sale of fixed assets and pension contributions. For free cash flow purposes, we consider contributions to pension plans to be more comparable to the payment of debt, and therefore exclude these contributions from the calculation of free cash flow.



Reconciliation of Income from Continuing Operations to Adjusted EBITDA Three Months Ended

	iviarch 31,		
(In millions)	2024 2023		
Income from continuing operations	\$ 22.7	\$	17.1
Income tax provision	8.1		4.6
Interest (income) expense, net	(2.8)		6.5
Depreciation and amortization	 22.1		22.7
EBITDA from continuing operations	50.1		50.9
Restructuring related costs ⁽¹⁾	1.1		0.8
Pension expense, other than service cost	1.0		0.2
M&A related costs ⁽²⁾	 5.2		2.5
Adjusted EBITDA from continuing operations	\$ 57.4	\$	54.4
Total revenue	\$ 392.3	\$	388.5
Adjusted EBITDA %	14.6%		14.0%



March 21

⁽¹⁾ Includes restructuring expense as well as any charges reported in cost of products for restructuring related inventory write-offs.

⁽²⁾ M&A related costs include integration costs, amortization of inventory step-up from business combinations, advisory and transaction costs for both potential and completed M&A transactions and strategy.

Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share

March 31,			,
2	2024	2	2023
\$	22.7	\$	17.1
	1.1		0.8
	5.2		2.5
	(1.6)		(0.9)
\$	27.4	\$	19.5
		1	
\$	22.7	\$	17.1
	32.2		32.1
\$	0.71	\$	0.53
		'	
\$	27.4	\$	19.5
	32.2		32.1
\$	0.85	\$	0.61
	\$ \$	\$ 22.7 \$ 1.1 5.2 (1.6) \$ 27.4 \$ 22.7 32.2 \$ 0.71 \$ 27.4 32.2	2024 2 \$ 22.7 \$ 1.1 5.2 (1.6) \$ \$ 27.4 \$ \$ 0.71 \$ \$ 27.4 \$



Three Months Ended

Reconciliation of Cash Provided by Operating Activities to Free Cash Flow

	Q1 2024			
(In millions)		YTD		TTM
Cash provided by operating activities	\$	10.4	\$	73.2
Less: Capital expenditures		10.5		49.3
Plus: Proceeds from disposal of assets		0.5		2.5
Plus: Pension contributions		0.3		12.1
Plus: income taxes on gain from sale of AeroTech				133.2
Free cash flow	\$	0.7	\$	171.7
Income from continuing operations	\$	22.7	\$	134.9
Free cash flow %		3%		127%



Leverage Ratio Calculations

(In millions)	Q	1 2024
Total debt	\$	647.0
Cash and marketable securities		(479.0)
Net debt		168.0
Other items considered debt under the credit agreement		15.9
Consolidated total indebtedness ⁽¹⁾	\$	183.9
Trailing twelve months Adjusted EBITDA from continuing operations	\$	276.1
Other adjustments net to earnings under the credit agreement		2.4
Consolidated EBITDA ⁽¹⁾	\$	278.5
Bank total net leverage ratio (Consolidated Total Indebtedness / Consolidated EBITDA)		0.7x
Total net debt to trailing twelve months Adjusted EBITDA from continuing operations		0.6x



⁽¹⁾ As defined in the credit agreement.

Recurring vs. Non-recurring Revenue

		As of		
	March	March 31, 2024		
Type of Good or Service				
Recurring ⁽¹⁾	\$	202.8		
Non-recurring ⁽¹⁾		189.5		
Total	\$	392.3		

% of recurring

52%

(1) Aftermarket parts and services and revenue from lease and longterm service contracts are considered recurring revenue. Non-recurring revenue includes new equipment and installation.



Reconciliation of Diluted Earnings Per Share from Continuing Operations to Adjusted Diluted Earnings Per Share Guidance

	Guidance
(In cents)	Full Year 2024
Diluted earnings per share from continuing operations	\$4.40 - \$4.80
Non-GAAP adjustments:	
Restructuring related costs ⁽¹⁾	0.03
M&A related costs ⁽²⁾	1.00
Bridge financing fees and related costs (3)	0.12
Impact on tax provision from Non-GAAP adjustments (4)	(0.25)
Impact on tax provision from tax planning actions (5)	(0.25)
Adjusted diluted earnings per share from continuing operations	\$5.05 - \$5.45

- (1) Restructuring related costs is estimated to be approximately \$1 million for the full year 2024. The mid-point amount has been divided by our estimate of 32.2 million total shares and dilutive securities to derive earnings per share.
- (2) M&A related costs is estimated to be \$30 35 million for the full year 2024. The mid-point amount has been divided by our estimate of 32.2 million total shares and dilutive securities to derive earnings per share.
- (3) Bridge financing fees and related costs is estimated to be approximately \$4 million for the full year 2024. The mid-point amount has been divided by our estimate of 32.2 million total shares and dilutive securities to derive earnings per share.
- (4) Impact on tax provision was calculated using the Company's effective tax rate of approximately 22 to 23%.
- (5) Impact on tax provision from tax planning actions is estimated to be \$8 9 million for the full year 2024. The mid-point amount has been divided by our estimate of 32.2 million total shares and dilutive securities to derive earnings per share.



Guidance

Reconciliation of Income from Continuing Operations to Adjusted EBITDA Guidance

	Juluance
(In millions)	Full Year 2024
Income from continuing operations	\$142.0 - \$154.0
Income tax provision	31.5 - 34.5
Interest income, net	~(2.0)
Depreciation and amortization	~90.0
EBITDA from continuing operations	261.5 - 276.5
Restructuring related costs	~1.0
Pension expense, other than service cost	-
M&A related costs	~32.5
Adjusted EBITDA from continuing operations	\$295.0 - \$310.0
	·



Guidance